Glass House Brands Inc. Subordi (GLAS) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.02

Estimate

-$0.06

Surprise

+67.5%

Score today

5.1/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Glass House Brands Inc. Subordi (GLAS) reported a narrower loss than forecast — diluted EPS of -$0.02 against the -$0.06 estimate (a 67.5% beat on a still-unprofitable quarter).

• Swarmer Posts Downbeat Q2 Results, Joins TSS, ARS Pharmaceuticals, Globant And Other Big Stocks Moving Lower In Friday’s — benzinga, 2026-08-14
• Glass House Brands Q2 2026 Earnings Call Transcript — benzinga, 2026-08-13

TrendMatrix currently rates GLAS Sell at 5.1/10; no pre/post engine snapshot brackets this report.

4 of the last 4 quarters beat the estimate; this quarter's +67.5% surprise compares with a +99.6% four-quarter average. Next scheduled report: 2026-11-11.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$9.79

Price target

$13.60

Stop

$9.10

Upside to target

+38.9%

Reward-to-risk

3.4:1

Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Drug Manufacturers - Specialty & Generic

Market cap

$922.6M

P/E (fwd)

43.5

52-week range

$5.15–$13.93

Off 52-week high

29.7%

RSI (14)

47

Volume vs avg

0.68×

Score today

5.1/10